Last edition
News about "Pierre Fabre "
US FDA Accepts Tabelecleucel BLA Resubmission for EBV-PTLD
The US FDA has accepted Pierre Fabre’s tabelecleucel BLA resubmission for EBV-positive PTLD, with a target decision date of March 31, 2027.
Pierre Fabre | 15/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members